Schumacher Markus B, Jongen Stefan, Knoche Anja, Petzke Frank, Vuurman Eric F, Vollrath Mark, Ramaekers Johannes G
Federal Highway Research Institute (BASt), Bruederstrasse 53, D-51427, Bergisch Gladbach, Germany.
Department of Neuropsychology and Psychopharmacology, Faculty of Psychology and Neuroscience, Maastricht University, Universiteitssingel 40, Maastricht, 6200 MD, The Netherlands.
Psychopharmacology (Berl). 2017 Mar;234(6):989-999. doi: 10.1007/s00213-017-4539-3. Epub 2017 Feb 12.
Chronic non-cancer pain (CNCP) is a major health problem. Patients are increasingly treated with chronic opioid therapy (COT). Several laboratory studies have demonstrated that long-term use of opioids does not generally impair driving related skills. But there is still a lack of studies investigating on-the-road driving performance in actual traffic.
The present study assessed the impact of COT on road-tracking and car-following performance in CNCP patients.
Twenty CNCP patients, long-term treated with stable doses of opioid analgesics, and 19 healthy controls conducted standardized on-the-road driving tests in normal traffic. Performance of controls with a blood alcohol concentration (BAC) of 0.5 g/L was used as a reference to define clinically relevant changes in driving performance.
Standard Deviation of Lateral Position (SDLP), a measure of road-tracking control, was 2.57 cm greater in CNCP patients than in sober controls. This difference failed to reach statistical significance in a superiority test. Equivalence testing indicated that the 95% CI around the mean SDLP change was equivalent to the SDLP change seen in controls with a BAC of 0.5 g/L and did not include zero. When corrected for age differences between groups the 95% CI widened to include both the alcohol reference criterion and zero. No difference was found in car-following performance.
Driving performance of CNCP patients did not significantly differ from that of controls due to large inter-individual variations. Hence in clinical practice determination of fitness to drive of CNCP patients who receive opioid treatments should be based on an individual assessment.
慢性非癌性疼痛(CNCP)是一个主要的健康问题。越来越多的患者接受慢性阿片类药物治疗(COT)。多项实验室研究表明,长期使用阿片类药物一般不会损害与驾驶相关的技能。但仍缺乏对实际交通中道路驾驶表现的研究。
本研究评估了COT对CNCP患者道路跟踪和跟车性能的影响。
20名长期接受稳定剂量阿片类镇痛药治疗的CNCP患者和19名健康对照者在正常交通情况下进行了标准化的道路驾驶测试。将血液酒精浓度(BAC)为0.5 g/L的对照组表现作为参考,以定义驾驶性能的临床相关变化。
横向位置标准差(SDLP)是衡量道路跟踪控制的指标,CNCP患者的SDLP比清醒对照组大2.57 cm。在优效性检验中,这一差异未达到统计学显著性。等效性检验表明,平均SDLP变化的95%置信区间与BAC为0.5 g/L的对照组的SDLP变化相当,且不包括零。在对组间年龄差异进行校正后,95%置信区间变宽,包括酒精参考标准和零。跟车性能未发现差异。
由于个体差异较大,CNCP患者的驾驶性能与对照组无显著差异。因此,在临床实践中,对接受阿片类药物治疗的CNCP患者驾驶适宜性的判定应基于个体评估。